{
    "nctId": "NCT00089999",
    "briefTitle": "Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer",
    "officialTitle": "A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients With Advanced or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 138,
    "primaryOutcomeMeasure": "Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee (IRC)",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Histologically confirmed invasive breast cancer with incurable stage IIIB, IIIC with T4 lesion or stage IV disease at primary diagnosis or at relapse after curative intent surgery.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Documented amplification of ErbB2 by Fluorescence in situ hybridization (FISH)\n* Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST)\n* Adequate renal, hepatic and cardiac function\n\nExclusion criteria:\n\n* Prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy other than adjuvant therapy. \\[Prior neo-adjuvant or adjuvant therapy (including trastuzumab) will be allowed provided it was stopped at least 12 months before study entry.\n* Patients with active brain metastases\n* Patients with bilateral breast cancer, bone metastases as the only disease site or metastases to more than 30% of the hepatic parenchyma.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}